On October 24, 2016, Juniper Pharmaceuticals filed its Form 8-K and said that it would be restating its financial statements since 2013 and that there were errors in its revenue in connection to a supply agreement with an affiliate of Germany's Merck KGaA. Following this news, Juniper Pharmaceuticals stock dropped 10% in early morning trading on October 25, 2016.
If you are aware of any facts relating to this investigation, or purchased shares Juniper, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/jnp. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-juniper-pharmaceuticals-inc-jnp-300352801.html
SOURCE Bronstein, Gewirtz & Grossman, LLC